Dr. Nagpal reviews frontline CNS data from the FLAURA2 and MARIPOSA trials, noting the importance of CNS-specific endpoints now being routinely incorporated into NSCLC clinical trials. Both trials enrolled patients with stable, predominantly pre-treated brain metastases.
Dr. Alder raises the inconsistency of CNS surveillance across practice settings in EGFR-mutated NSCLC, noting that even within the FLAURA2 and MARIPOSA trials, brain MRI schedules were not uniform. She asks Dr. Nagpal to address evidence-based surveillance recommendations and the barriers to implementing them.
